GH Research (GHRS) Non-Current Assets (2021 - 2025)
GH Research (GHRS) recorded quarterly Non-Current Assets of $134.2 million in Q4 2025, up 1756.21% quarter-over-quarter from $7.2 million in Q3 2025, and down 16.14% on a YoY basis from $160.1 million in Q4 2024.
GH Research (GHRS) Non-Current Assets (2021 - 2025) Analysis & Trends
GH Research's Non-Current Assets history runs 5 years deep, the most recent figure standing at $134.2 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 16.14% year-over-year to $134.2 million; the TTM figure through Dec 2025 stood at $134.2 million (down 16.14% YoY), while the FY2025 annual figure was $134.2 million, down 16.14% from the prior year.
- Non-Current Assets was $134.2 million for Q4 2025 at GH Research, up from $7.2 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $160.1 million in Q4 2024 to a low of $73000.0 in Q3 2021.
- Historically, Non-Current Assets has averaged $55.6 million across 5 years, with a median of $55.6 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets soared 104272.84% in 2023, then slumped 83.81% in 2025.
- A 5-year view of Non-Current Assets shows it stood at $122.1 million in 2021, then decreased by 29.7% to $85.8 million in 2022, then decreased by 27.51% to $62.2 million in 2023, then soared by 157.3% to $160.1 million in 2024, then fell by 16.14% to $134.2 million in 2025.
- The last three Non-Current Assets figures came in at $134.2 million (Q4 2025), $7.2 million (Q3 2025), and $19.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 62,953.78 |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 30.30 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | 39.71 Mn |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 134.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 134.24 Mn |
| Sep 30, 2025 | 7.23 Mn |
| Jun 30, 2025 | 19.55 Mn |
| Mar 31, 2025 | 25.79 Mn |
| Dec 31, 2024 | 160.07 Mn |
| Sep 30, 2024 | 44.67 Mn |
| Jun 30, 2024 | 54.07 Mn |
| Mar 31, 2024 | 57.11 Mn |
| Dec 31, 2023 | 62.21 Mn |
| Sep 30, 2023 | 68.53 Mn |
| Jun 30, 2023 | 73.87 Mn |
| Mar 31, 2023 | 84.54 Mn |
| Dec 31, 2022 | 85.82 Mn |
| Sep 30, 2022 | 84,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 122.08 Mn |
| Sep 30, 2021 | 73,000.00 |